NCT Number: NCT01740037
IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients With Atrial Fibrillation - RACE4
Rationale: The treatment of patients with atrial fibrillation is often inadequate due to poor guideline adherence. An integrated chronic care program (ICCP) at a specialized AF-clinic was found to be superior to usual care provided by a cardiologist in terms of cardiovascular hospitalizations and cardiovascular mortality.
Hypothesis: treatment at a specialized AF clinic is superior to usual care in terms of cardiovascular mortality and cardiovascular hospitalizations, cost-effectiveness, quality of life and guideline adherence.
Objectives: primary objective is to show that an ICCP reduces cardiovascular hospitalizations and mortality.
Study design: randomized controlled trial with two study arms: usual care provided by cardiologists (control) versus integrated chronic care program at a specialized AF clinic (intervention) in 8 hospitals in the Netherlands. The RACE4 is an event driven study. A total number of 246 events is needed. In total 1716 patients with newly diagnosed AF will be included. Total duration of the study is 5 years and 10 months with a minimal follow up of 1 year. Data is collected at inclusion, after 3, 6, 12 months, every year thereafter and at the end of the study.
Study population: Patients older than 18 year with newly diagnosed AF.
Intervention: The intervention is delivered through the specialized outpatient AF clinic. The multidisciplinary team at the AF clinic consists of a nurse practitioner or physician assistant or specialised cardiovascular nurse, cardiologist, and is guided by guidelines-based decision support software program based on the applicable ESC guideline recommendations. The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Martini Ziekenhuis, Groningen, Netherlands
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with newly diagnosed AF detected on electrocardiogram (ECG), holter recordings or event recorder with a duration > 30 seconds, 3 months before inclusion or
- Patients with a history of diagnosed AF, with no regular control at a cardiologist for AF in the last 2 years and referred by a (non-)cardiologic medical specialist for new diagnostics or therapeutic issue;
- Age ≥18 years.
Exclusion criteria
- No electrocardiographic objectified AF;
- Unstable heart failure defined as NYHA IV or heart failure necessitating hospital admission < 3 months before inclusion;
- Acute coronary syndrome (acute myocardial infarction or instable angina pectoris, with two of the following characteristics: chest pain and/ or ischemic electrocardiographic changes, and/ or cardiac enzyme rise) < 3 months before inclusion;
- Untreated hyperthyroidism or < 3 months euthyroidism before inclusion;
- Foreseen pacemaker, internal cardioverter defibrillator, and/ or cardiac resynchronization therapy;
- Cardiac surgery ≤ 3 months before inclusion;
- Planned cardiac surgery;
- Regular control and treatment, also for AF, at another specialized outpatient cardiac clinic;
- Patient is not able to fill in the questionnaires;
- Participation in other clinical study.
Treatment and study plan
Usual Care
OtherPrimary outcomes
-
The primary endpoint is a composite of unplanned admission to the hospital for any cardiovascular reason and cardiovascular death.
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
Secondary outcomes
-
All components of the primary endpoint
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
All-cause mortality
Time frame: Minimum of 1 year and a maximum of 5 years and 10 months
-
Total number of unplanned all-cause hospitalizations
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Duration of unplanned all-cause hospitalizations
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Total number of unplanned cardiovascular hospitalizations
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Duration of unplanned cardiovascular hospitalizations
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Total number of unplanned hospitalizations related to atrial fibrillation
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Duration of unplanned hospitalizations related to atrial fibrillation
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Recurrent unplanned cardiovascular hospitalizations
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
-
Costs and cost-effectiveness
Time frame: baseline, 1 year, 2 years, 3 years
Costs, Quality Adjusted Life Years (QALYs) and Cost-effectiveness (Incremental Cost-Effectiveness Ratio - ICER)
-
Implementation of care
Time frame: Follow up with minimum of 1 year and a maximum of 5 years and 10 months
The extent to which the comprehensive cardiovascular treatment is in accordance with the most recent ESC guidelines Management of Atrial Fibrillation, the HF guidelines of acute and chronic heart failure and the CVD prevention guidelines
-
Patient Quality of life
Time frame: Baseline, 1 year, 2 years, 3 years
General health-related QoL is measured by using the SF-36
-
Patient Quality of life
Time frame: Baseline, 1 year, 2 years, 3 years
Patient's perception of severity of arrhythmia-related symptoms is measured by using the AFSS
-
Anxiety and/ or depression
Time frame: Baseline, 1 year, 2 years, 3 years
HADS-NL
-
Knowledge of AF
Time frame: Baseline, 1 year, 2 years, 3 years
Netherlands Knowledge Scale on AF
-
Compliance to medication
Time frame: Baseline, 1 year, 2 years, 3 years
MMAS
-
Compliance to medication
Time frame: Baseline, 1 year, 2 years, 3 years
To measure the level of activation of a specific individual the PAM-13 Dutch is used
Sponsors and collaborators
Lead sponsor
Maastricht University Medical Center
Other
Collaborators
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- CZ Fonds
- DSW
- Daiichi Sankyo
- Pfizer
- Stichting Achmea Gezondheidszor
Registry information
Official study title
IntegRAted Chronic Care Program at a Specialized Atrial Fibrillation (AF) Clinic Versus Usual CarE in Patients With Atrial Fibrillation, an Investigator-initiated, Prospective, Randomised, Open Label, Blinded Outcome Assessment (PROBE) Controlled Multi-center Study
Acronym: RACE4
Important dates
- Study start
- 2012
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Dec 4, 2012
- Registry last updated
- May 28, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Ground-Breaking Electroporation-based Intervention for PAROXysmal Atrial Fibrillation Treatment (BEAT PAROX-AF)
NCT05159492
Arrhythmias, Cardiac, Atrial Fibrillation
Graz, Austria
View Trial DetailsThe Effect of an Intervention Based on The CSM on Self-Management in Patients After Atrial Fibrillation Ablation
NCT07741682
Arrhythmias, Cardiac, Atrial Fibrillation
Qingdao, Shandong, China
View Trial DetailsImproving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination
NCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial DetailsEffect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
NCT05993897
Arrhythmias, Cardiac, Atrial Fibrillation
Aswān, Aswan Governorate, Egypt
View Trial Details